信中医药科技（北京）有限公司

Xinzong Pharmaceutical Technology (Beijing) Co., Ltd. is a biotechnology company based in Beijing, China, primarily focused on the research and development of innovative small molecule drugs for oncology. As an R&D entity associated with the ChinaEquity Group (信中利), the company develops targeted therapies, including inhibitors for the Epidermal Growth Factor Receptor (EGFR) to address resistance mutations like T790M in lung cancer. Its intellectual property includes patents for various substituted pyrimidine and heterocyclic compounds with potential applications in treating solid tumors. The company currently operates in the pre-clinical stage, focusing on drug discovery and early-stage lead optimization. Headquartered in Beijing, Xinzong Pharmaceutical Technology leverages its connection to the ChinaEquity investment network to support its pharmaceutical innovation goals.